Literature DB >> 25586394

Scopolamine provocation-based pharmacological MRI model for testing procognitive agents.

Nikolett Hegedűs1, Judit Laszy2, István Gyertyán2, Pál Kocsis3, Dávid Gajári3, Szabolcs Dávid3, Levente Deli3, Zsófia Pozsgay3, Károly Tihanyi3.   

Abstract

There is a huge unmet need to understand and treat pathological cognitive impairment. The development of disease modifying cognitive enhancers is hindered by the lack of correct pathomechanism and suitable animal models. Most animal models to study cognition and pathology do not fulfil either the predictive validity, face validity or construct validity criteria, and also outcome measures greatly differ from those of human trials. Fortunately, some pharmacological agents such as scopolamine evoke similar effects on cognition and cerebral circulation in rodents and humans and functional MRI enables us to compare cognitive agents directly in different species. In this paper we report the validation of a scopolamine based rodent pharmacological MRI provocation model. The effects of deemed procognitive agents (donepezil, vinpocetine, piracetam, alpha 7 selective cholinergic compounds EVP-6124, PNU-120596) were compared on the blood-oxygen-level dependent responses and also linked to rodent cognitive models. These drugs revealed significant effect on scopolamine induced blood-oxygen-level dependent change except for piracetam. In the water labyrinth test only PNU-120596 did not show a significant effect. This provocational model is suitable for testing procognitive compounds. These functional MR imaging experiments can be paralleled with human studies, which may help reduce the number of false cognitive clinical trials.
© The Author(s) 2015.

Entities:  

Keywords:  BOLD; cognition; cognitive enhancer; fMRI; nootropics; rat; scopolamine; water labyrinth test

Mesh:

Substances:

Year:  2015        PMID: 25586394     DOI: 10.1177/0269881114565652

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  3 in total

1.  Why an M1 Antagonist Could Be a More Selective Model for Memory Impairment than Scopolamine.

Authors:  Arjan Blokland; Anke Sambeth; Jos Prickaerts; Wim J Riedel
Journal:  Front Neurol       Date:  2016-09-30       Impact factor: 4.003

Review 2.  Strategies for Utilizing Neuroimaging Biomarkers in CNS Drug Discovery and Development: CINP/JSNP Working Group Report.

Authors:  Tetsuya Suhara; Shigeyuki Chaki; Haruhide Kimura; Makoto Furusawa; Mitsuyuki Matsumoto; Hiroo Ogura; Takaaki Negishi; Takeaki Saijo; Makoto Higuchi; Tomohiro Omura; Rira Watanabe; Sosuke Miyoshi; Noriaki Nakatani; Noboru Yamamoto; Shyh-Yuh Liou; Yuhei Takado; Jun Maeda; Yasumasa Okamoto; Yoshiaki Okubo; Makiko Yamada; Hiroshi Ito; Noah M Walton; Shigeto Yamawaki
Journal:  Int J Neuropsychopharmacol       Date:  2017-04-01       Impact factor: 5.176

3.  Deciphering the scopolamine challenge rat model by preclinical functional MRI.

Authors:  Gergely Somogyi; Dávid Hlatky; Tamás Spisák; Zsófia Spisák; Gabriella Nyitrai; András Czurkó
Journal:  Sci Rep       Date:  2021-05-25       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.